GI1/2 inhibitor, arsenic trioxide, decreases KIT expression and reduces cell viability by significantly increasing the bonding of GLI3 to the KIT promoter, demonstrating efficacy in the Imatinib-sensitive and Imatinib-resistant GIST cells [157]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.